Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Alexander Drilon, MD

    Alexander Drilon, MD

    Medical Oncologist
    Memorial Sloan Kettering Cancer Center
    New York, NY, USA


    Related Videos

    At what stage in the presentation of NSCLC should one consider doing comprehensive NGS with hybrid capture? Video

    At what stage in the presentation of NSCLC should one consider doing comprehensive NGS with hybrid capture?

    At what stage in the presentation of NSCLC should one consider doing comprehensive NGS with hybrid capture?

    What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected? Video

    What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected?

    What is the importance of the gene encoding the ROS1 proto-oncogene receptor tyrosine kinase (ROS1) as a distinct molecular subgroup of NSCLC? In what percentage of patients is ROS1 detected? What is the role of crizotinib in these patients?

    If MET amplification is documented in NSCLC, why is crizotinib considered to have "targeted activity" against this tumor profile? What support suggests high activity in patients with tumors manifesting this genetic alteration? Video

    If MET amplification is documented in NSCLC, why is crizotinib considered to have "targeted activity" against this tumor profile? What support suggests high activity in patients with tumors manifesting this genetic alteration?

    If MET amplification is documented in NSCLC, why is crizotinib considered by the NCCN to have “targeted activity” against this tumor profile? What clinical study-based support—improvements in PFS and/or OS—suggests high activity of this ...

    Can you provide an overview of the actionable targets--such as EGFR, ALK, and MET--that are relevant for patients with NSCLC, and how to deploy NGS technologies to identify molecular drivers? Video

    Can you provide an overview of the actionable targets--such as EGFR, ALK, and MET--that are relevant for patients with NSCLC, and how to deploy NGS technologies to identify molecular drivers?

    Can you provide an overview of the clinically actionable targets—such as EGFR, ALK, and MET—that are relevant for patients with NSCLC, and how to optimally deploy NGS technologies to identify molecular drivers in the clinic setting?

    What is the rationale for referring this patient to a phase II study of cabozantinib or other multi-TKI if she had had surgery and chemotherapy, but shows progression after cytotoxic chemotherapy? Video

    What is the rationale for referring this patient to a phase II study of cabozantinib or other multi-TKI if she had had surgery and chemotherapy, but shows progression after cytotoxic chemotherapy?

    What would be the rationale for referring this patient to a phase II study of cabozantinib or other multi-TKI if she had had surgery and chemotherapy, but shows progression to Stage IV disease after two prior lines of cytotoxic chemotherapy?

    How would you approach a middle-aged female, non-smoker diagnosed with stage 1-B lung adenocarcinoma in which the FoundationOne CGP identified a TRIM33-RET fusion? Video

    How would you approach a middle-aged female, non-smoker diagnosed with stage 1-B lung adenocarcinoma in which the FoundationOne CGP identified a TRIM33-RET fusion?

    How would you approach a middle-aged female, non-smoker is diagnosed with stage 1–B lung adenocarcinoma in which the FoundationOne CGP identified a TRIM33–RET fusion. What would be the “target-focused” treatment and timing implications of this finding?

    What are currently the most important actionable drivers, from a mutational perspective, for lung cancer? And what is the emerging importance of RET kinase inhibitors? Video

    What are currently the most important actionable drivers, from a mutational perspective, for lung cancer? And what is the emerging importance of RET kinase inhibitors?

    What are currently the most important actionable drivers, from a mutational perspective, for lung cancer? And what is the emerging importance of RET kinase inhibitors?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED